Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for Inhibrx Biosciences (INBX) over the last 1 years, with Sep 2025 value amounting to -$7,000.

  • Inhibrx Biosciences' Cash from Investing Activities rose 97.17% to -$7,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$291,000, marking a year-over-year increase of 95.17%. This contributed to the annual value of -$2.6 million for FY2024, which is 43.46% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Cash from Investing Activities is -$7,000, which was up 66.67% from -$21,000 recorded in Q1 2025.
  • In the past 5 years, Inhibrx Biosciences' Cash from Investing Activities registered a high of -$7,000 during Q3 2025, and its lowest value of -$3.4 million during Q4 2023.
  • In the last 3 years, Inhibrx Biosciences' Cash from Investing Activities had a median value of -$529,000 in 2023 and averaged -$859,750.
  • Data for Inhibrx Biosciences' Cash from Investing Activities shows a peak YoY skyrocketed of 99.54% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Cash from Investing Activities stood at -$3.4 million in 2023, then soared by 99.54% to -$16,000 in 2024, then soared by 97.17% to -$7,000 in 2025.
  • Its last three reported values are -$7,000 in Q3 2025, -$21,000 for Q1 2025, and -$16,000 during Q4 2024.